Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells

Laboratory Investigation

Volumn 89, Issue 12, 2009, Pages 1423-1432

  Zhang, Peng ^a,b   Zhao, Nianxi ^a   Zeng, Zihua ^a   Feng, Yongdong ^a,b   Tung, Ching Hsuan ^a   Chang, Chung Che ^a   Zu, Youli ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Aptamer probe; CD30 expression; Cell binding; Flow cytometry analysis; Lymphoma diagnosis; RNA oligonucleotide

Indexed keywords

CD30 ANTIGEN; RNA;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; ANTIBODIES; ANTIGENS, CD30; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA; MICE; MOLECULAR PROBE TECHNIQUES; SENSITIVITY AND SPECIFICITY;

EID: 70549112254     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.113     Document Type: Article

References (34)

1. Ulrich H, Martins AH, Pesquero JB. RNA and DNA aptamers in cytomics analysis. Cytometry A 2004;59:220-231.
2. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-822.
3. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (NY) 1990;249:505-510.
4. Brody EN, Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000;74:5-13.
5. Fredriksson S, Gullberg M, Jarvius J, et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol 2002;20:473-477.
6. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu Rev Med 2005;56:555-583.
7. Bunka DH, Stockley PG. Aptamers come of age-at last. Nat Rev 2006;4:588-596.
8. Cerchia L, Hamm J, Libri D, et al. Nucleic acid aptamers in cancer medicine. FEBS Lett 2002;528:12-16.
9. Mori T, Oguro A, Ohtsu T, et al. RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res 2004;32:6120-6128.
10. Nawrocki JF, Kirsten ES, Fisher RI. Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J Immunol 1988;141:672-680.
11. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-858.
12. Chiarle R, Podda A, Prolla G, et al. CD30 in normal and neoplastic cells. Clin Immunol 1999;90:157-164.
13. Delsol GJE, Faini B, Gascoyne RD, et al. Anaplastic large cell lymphoma (ALCL), ALK positive. In: Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumors of Haematopoietic and Lymphod Tissues. WHO Press: Lyon, France, 2008, pp 312-316.
14. Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol 2007;127:707-722.
15. Staber PB, Noehammer C, Durkop H, et al. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. Leuk Res 2006;30:343-348.
16. Hirsch B, Hummel M, Bentink S, et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008;172:510-520.
17. Wendtner CM, Schmitt B, Gruss HJ, et al. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line. Cancer Res 1995;55:4157-4161.
18. Hubinger G, Muller E, Scheffrahn I, et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 2001;20:590-598.
19. Levi E, Pfeifer WM, Kadin ME. CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest? Blood 2001;98:1630-1632.
20. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000;96:4307-4312.
21. Nishikori M, Ohno H, Haga H, et al. Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci 2005;96:487-497.
22. Hubinger G, Schneider C, Stohr D, et al. CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells. Exp Hematol 2004;32:382-389.
23. Mukhopadhyay R. APTAMERS ARE READY FOR. Anal Chem 2005;77:114A-118A.
24. Hodgkin PD, Lee JH, Lyons AB. B cell differentiation and isotype switching is related to division cycle number. J Exp Med 1996;184: 277-281.
25. Stewart CC, Behm FG, Carey JL, et al. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations. Cytometry 1997;30:231-235.
26. Kaur G, Roy I. Therapeutic applications of aptamers. Expert Opin Investig Drugs 2008;17:43-60.
27. Schneider C, Hubinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 2002;43:1355-1366.
28. Heuck F, Ellermann J, Borchmann P, et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J Immunother 2004;27:347-353.
29. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-3742.
30. Kusser W. Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution. J Biotechnol 2000;74: 27-38.
31. Ulrich H. RNA aptamers: from basic science towards therapy. Handb Exp Pharmacol 2006;305-326.
32. Stoltenburg R, Reinemann C, Strehlitz B. SELEX-a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 2007;24:381-403.
33. Keefe AD, Cload ST. SELEX with modified nucleotides. Curr Opin Chem Biol 2008;12:448-456.
34. Minakawa N, Sanji M, Kato Y, et al. Investigations toward the selection of fully-modified 40-thioRNA aptamers: optimization of in vitro transcription steps in the presence of 40-thioNTPs. Bioorg Med Chem 2008;16:9450-9456.